Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies.

Rockberg J, Schwenk JM, Uhlén M.

Mol Oncol. 2009 Jun;3(3):238-47. doi: 10.1016/j.molonc.2009.01.003. Epub 2009 Jan 31.

2.

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T.

BMC Cancer. 2012 Oct 4;12:450. doi: 10.1186/1471-2407-12-450.

3.

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H.

Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12.

4.

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M.

Mol Cancer Ther. 2015 Mar;14(3):669-80. doi: 10.1158/1535-7163.MCT-14-0697. Epub 2015 Jan 22.

5.

Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.

Di Modugno F, Buglioni S, Mottolese M, Bello DD, Cascioli S, Chersi A, Santoni A, Nisticò P.

J Immunother. 2001 May-Jun;24(3):221-31.

PMID:
11394499
6.

A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.

Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT.

J Immunol. 2003 Apr 15;170(8):4242-53.

7.

Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.

Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU.

Mol Cancer Ther. 2005 Jun;4(6):956-67.

8.

Purification and characterization of recombinant extracellular domain of human HER2 from Escherichia coli.

Liu X, He Z, Zhou M, Yang F, Lv H, Yu Y, Chen Z.

Protein Expr Purif. 2007 Jun;53(2):247-54. Epub 2006 Oct 24.

PMID:
17257855
9.

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.

Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V.

FASEB J. 2011 Jul;25(7):2433-46. doi: 10.1096/fj.10-180331. Epub 2011 Apr 8.

PMID:
21478264
10.

Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.

Kobayashi H, Wood M, Song Y, Appella E, Celis E.

Cancer Res. 2000 Sep 15;60(18):5228-36.

11.

Design of an optimized scaffold for affibody molecules.

Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, Galli J, Jonasson P, Abrahmsén L.

J Mol Biol. 2010 Apr 30;398(2):232-47. doi: 10.1016/j.jmb.2010.03.002. Epub 2010 Mar 10.

PMID:
20226194
12.

Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.

Deng X, Zheng X, Yang H, Moreira JM, Brünner N, Christensen H.

PLoS One. 2014 Sep 5;9(9):e106448. doi: 10.1371/journal.pone.0106448. eCollection 2014.

13.

Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies.

Daniele L, Sapino A.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):9-18. Review.

PMID:
19149684
15.
16.

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, Xu Q, He L, Tan W, Bethune AN, Zhou L.

MAbs. 2014 Jul-Aug;6(4):978-90. doi: 10.4161/mabs.28786. Epub 2014 Apr 16.

17.
18.

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES.

MAbs. 2014 Mar-Apr;6(2):340-53. doi: 10.4161/mabs.27658. Epub 2013 Dec 26.

19.

Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.

Mahdavi M, Mohabatkar H, Keyhanfar M, Dehkordi AJ, Rabbani M.

Asian Pac J Cancer Prev. 2012;13(7):3053-9.

20.

Generation of HER2 monoclonal antibodies using epitopes of a rabbit polyclonal antibody.

Hu FJ, Uhlen M, Rockberg J.

N Biotechnol. 2014 Jan 25;31(1):35-43. doi: 10.1016/j.nbt.2013.10.002. Epub 2013 Oct 11.

PMID:
24120493

Supplemental Content

Support Center